Loading clinical trials...
Loading clinical trials...
Conditions
Interventions
Gen 2 Travoprost Intracameral Implant
Timolol eye drops 0.5%
+2 more
Locations
3
United States
Glaukos Investigative Site
Grand Junction, Colorado, United States
Glaukos Investigative Site
Oklahoma City, Oklahoma, United States
Glaukos Clinical Site
El Paso, Texas, United States
Start Date
June 12, 2025
Primary Completion Date
March 1, 2028
Completion Date
March 1, 2032
Last Updated
March 2, 2026
NCT07539675
NCT06289491
NCT07496957
NCT04354545
NCT07298356
NCT07396441
Lead Sponsor
Glaukos Corporation
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions